Assertio Therapeutics Stock News

Investors need to pay close attention to Assertio (ASRT) stock based on the movements in the options market lately.

Investors need to pay close attention to Assertio (ASRT) stock based on the movements in the options market lately.

Assertio (NASDAQ: ASRT ) stock is falling hard on Friday after the pharmaceutical company released its Q2 earnings report. Assertio disappointed investors with its adjusted earnings per share of 19 c

The stock is down 33% from its 52-week high. Q2 revenue estimates are low. Lead product's use may be expanding.

Spectrum stockholders will receive contingent value rights, too, along with Assertio shares. The rewards are payable on achievement of 2024 and 2025 sales levels from Spectrum's lead drug. Rolvedon ha

The Supreme Court recently nullified the Biden administration's proposed student loan forgiveness program in a 6-3 ruling. Seen as overreaching the authority of the executive branch, this program inte

Assertio is a late-stage pharmaceutical company that has shown significant growth and cost savings under new leadership, focusing on a low-cost, data-driven marketing model. The company's leading prod

Share portion of takeover by Assertio Holdings covers the value of the shares plus a merger spread. Contingent value rights on their drug are also included, adding up to $0.20 per share. CVR payout wi

Assertio Holdings, a pharmaceutical company, has demonstrated solid financials and growth potential, with a focus on reducing debt levels and increasing cash generation through strategic acquisitions.

In Q1 FY2023, Assertio achieved significant progress in executing the new strategy brought on board by CEO Dan Peisert. The market expects ASRT's EPS to decline nearly 82% YoY in FY2023, but then rebo

Assertio Holdings, Inc. (NASDAQ:ASRT ) Q1 2023 Results Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Matt Kreps - Darrow Associates, Investor Relations Dan Peisert - President

The world's foremost artificial intelligence stock trading algorithm, An-E, predicts that Assertio (NASDAQ: ASRT ) stock will gain 3% by June 1. An-E (pronounced Annie) has made this kind of predictio

Assertio Holdings stock has fallen 8.15% since my updated bullish thesis in March 2023, while the S&P 500 Index has gained 4.95% over the same period. The SPPI deal is expected to give Assertio access

LAKE FOREST, Ill., April 27, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products

Spectrum Pharmaceuticals (NASDAQ:SPPI) stock is soaring after an all-stock acquisition deal with Assertio Holdings was announced Tuesday morning.  The $248 million purchase price values Spectrum sha